Patents by Inventor Frederic J. de Sauvage

Frederic J. de Sauvage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gene disruptions, compositions and methods relating thereto
    Patent number: 7931902
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO226, PRO257, PRO268, PRO290, PRO36006, PRO363, PRO365, PRO382, PRO444, PRO705, PRO1071, PRO1125, PRO1134, PRO1155, PRO1281, PRO1343, PRO1379, PRO1380, PRO1387, PRO1419, PRO1433, PRO1474, PRO1550, PRO1571, PRO1572, PRO1759, PRO1904, PRO35193, PRO4341, PRO4348, PRO4369, PRO4381, PRO4407, PRO4425, PRO4985, PRO4989, PRO5737, PRO5800, PRO5993, PRO6017, PRO7174, PRO9744, PRO9821, PRO9852, PRO9873, PRO10196, PRO34778, PRO20233, PRO21956, PRO57290, PRO38465, PRO38683 or PRO85161 genes.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: April 26, 2011
    Assignee: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Gretchen Frantz, Charles Montgomery, Franklin Peale, Zheng-Zheng Shi, Mary Jean Sparks
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC
    Publication number: 20110070243
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: September 9, 2010
    Publication date: March 24, 2011
    Inventors: CRAIG CROWLEY, FREDERIC J. DE SAUVAGE, DAN L. EATON, ALLEN EBENS, JR., KRISTI ELKINS, JO-ANNE S. HONGO, JAGATH REDDY JUNUTULA, ANDREW POLSON, SARAJANE ROSS, VICTORIA SMITH, RICHARD L. VANDLEN, BING ZHENG
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN
    Publication number: 20110045005
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: April 7, 2010
    Publication date: February 24, 2011
    Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebens, JR., Andrew Polson, Victoria Smith
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN
    Publication number: 20110042260
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: August 12, 2010
    Publication date: February 24, 2011
    Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebens, JR., Jo-Anne S. Hongo, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Patent number: 7888478
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: February 15, 2011
    Assignee: Genentech, Inc.
    Inventors: Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • Gene disruptions, compositions and methods relating thereto
    Patent number: 7858843
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: December 28, 2010
    Assignee: Genentech, Inc.
    Inventors: Ling Ling Culbertson, Frederic J. de Sauvage, Charles Montgomery, Zheng-Zheng Shi, Mary Jean Sparks
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Patent number: 7858330
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: December 28, 2010
    Assignee: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen D. Frantz, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • Methods of screening for agonists and antagonists of patched-2
    Patent number: 7811777
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, antibodies, vectors and host cells expressing, immunoadhesins, agonists and antagonists to patched-2.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: October 12, 2010
    Assignee: Genentech Inc.
    Inventors: Frederic J. de Sauvage, David A. Carpenter
  • GFRALPHA3 AND ITS USES
    Publication number: 20100249034
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFR?3, a novel ?-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an ?-subunit receptor by detecting tyrosine kinase receptor activation (i.e., autophosphorylation) or other activities related to ligand-induced ?-subunit receptor homo-dimerization or homo-oligomerization.
    Type: Application
    Filed: February 2, 2010
    Publication date: September 30, 2010
    Inventors: Frederic J. de Sauvage, Robert D. Klein, Heidi S. Phillips, Arnon Rosenthal
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Patent number: 7754441
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: July 13, 2010
    Assignee: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Andrew Polson, Victoria Smith, Suzie J. Scales
  • METHOD FOR USING CDO ANTAGONISTS TO MODULATE HEDGEHOG SIGNALING
    Publication number: 20100098624
    Abstract: The present invention provides for a method of using BOC/CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation, chondrogenesis and osteogenesis, lung surfactant production, formation of lamellated bodies in lung cells.
    Type: Application
    Filed: December 1, 2009
    Publication date: April 22, 2010
    Applicant: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Hua Tian
  • GFR?3 polypeptides
    Patent number: 7691973
    Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFR?3, a novel ?-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an ?-subunit receptor by detecting tyrosine kinase receptor activation (i.e., autophosphorylation) or other activities related to ligand-induced ?-subunit receptor homo-dimerization or homo-oligomerization.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: April 6, 2010
    Assignee: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Robert D. Klein, Heidi S. Phillips, Arnon Rosenthal
  • Persephin specific antibodies
    Patent number: 7649082
    Abstract: A novel growth factor, persephin, which belongs to the GDNF/neurturin family of growth factors, is disclosed. The human, mouse and rat amino acid sequences have been identified. Human, mouse and rat persephin genomic DNA sequences have been cloned and sequenced and the respective cDNA sequences identified. In addition, methods for treating degenerative conditions using persephin, methods for detecting persephin gene alterations and methods for detecting and monitoring patient levels of persephin are provided. Methods for identifying additional members of the persephin-neurturin-GDNF family of growth factors are also provided.
    Type: Grant
    Filed: January 18, 2005
    Date of Patent: January 19, 2010
    Assignees: Washington University, Genentech, Inc.
    Inventors: Eugene M. Johnson, Jeffrey D. Milbrandt, Paul T. Kotzbauer, Patricia A. Lampe, Robert D. Klein, Frederic J. de Sauvage
  • Novel Gene Disruptions, Compositions and Methods Relating Thereto
    Publication number: 20090313707
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes.
    Type: Application
    Filed: May 18, 2006
    Publication date: December 17, 2009
    Applicants: Genentech, Inc., Lexicon Pharamaceuticals, Inc.
    Inventors: Katherin E. Combs, Ling Ling Culbertson, Frederic J. de Sauvage, Zhiyong Ding, Joel Edwards, Rosemary Girgis, Allison A. B. Horner, Harald Junge, Jagath Reddy Junutula, Erin Marie Massey, Dina R. McLain, Charles Montgomery, Bobby Joe Payne, Heidi Phillips, Ni Nancy Qian, Carolina Rangel, Tracy E. W. Sevaux, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Peter Vogel, Weilan Ye
  • Method for using BOC/CDO to modulate hedgehog signaling
    Patent number: 7625759
    Abstract: The present invention provides for a method of using BOC/CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such as hair growth, neural stem cell differentiation, chondrogenesis and osteogenesis, lung surfactant production, formation of lamellated bodies in lung cells.
    Type: Grant
    Filed: January 22, 2007
    Date of Patent: December 1, 2009
    Assignee: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Hua Tian
  • Novel Gene Disruptions, Compositions and Methods Relating Thereto
    Publication number: 20090293137
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO 1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes.
    Type: Application
    Filed: November 16, 2006
    Publication date: November 26, 2009
    Applicant: Genentech, Inc.
    Inventors: Katherin E. Combs, Frederic J. de Sauvage, Liangfen Fan, Ellen Filvaroff, Allison A. B. Horner, Bryan Irving, Jagath Reddy Juntula, Erin Marie Massey, Dina Rebecca McLain, Laurie Jeanette Minze, Charles Montgomery, Bobby Joe Payne, Heidi Philips, Carolina Rangel, Tracy E. W. Sevaux, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Teresa G. Townsend, Peter Vogel
  • Novel Gene Disruptions, Compositions and Methods Relating Thereto
    Publication number: 20090288176
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO286, PRO706, PRO1800, PRO4354, PRO6029, PRO9739, PRO20044, PRO28631 or PRO34128 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.
    Type: Application
    Filed: April 18, 2007
    Publication date: November 19, 2009
    Applicant: Genentech, Inc.
    Inventors: Kristi Rae Bollinger, Frederic J. de Sauvage, Joel Edwards, Rosemary Girgis, Leslie Jane Green, Laurie Jeanette Minze, Bobby Joe Payne, Carolina Rangel, Zheng-Zheng Shi, Mary Jean Sparks, Tracy Tzu-Ling Tang, Peter Vogel
  • Assay methods for suppressor of fused modulation of hedgehog signaling
    Patent number: 7579161
    Abstract: The present invention is directed to novel polypeptides having homology to a polypeptide suppressor of the Drosophila melanogaster fused protein and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: August 25, 2009
    Assignee: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Maximilien Murone, Arnon Rosenthal, Donna M. Stone, Austin L. Gurney, William I. Wood
  • Compositions and methods for treatment of microbial disorders
    Publication number: 20090202475
    Abstract: The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions.
    Type: Application
    Filed: November 7, 2008
    Publication date: August 13, 2009
    Applicant: Genentech, Inc.
    Inventors: Alexander R. Abbas, Nico P. Ghilardi, Zora Modrusan, Dimitry M. Danilenko, Frederic J. De Sauvage, Wenjun Ouyang, Patricia A. Valdez, Yan Zheng
  • Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
    Publication number: 20090068178
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: January 31, 2008
    Publication date: March 12, 2009
    Applicant: Genentech, Inc.
    Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebens, JR., Kristi Elkins, Jo-Anne S. Hongo, Jagath Reddy Junutula, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen, Bing Zheng